DRAFT Guidance Document for Industry - Preparation and Submission of Summary Reports for Marketed Health Products

Size: px
Start display at page:

Download "DRAFT Guidance Document for Industry - Preparation and Submission of Summary Reports for Marketed Health Products"

Transcription

1 DRAFT Preparation and Submission of Summary Reports for Marketed Health Products Annual Summary Reports and Issue-Related Summary Reports (effective date: Month dd, yyyy)

2 Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. We assess the safety of drugs and many consumer products, help improve the safety of food, and provide information to Canadians to help them make healthy decisions. We provide health services to First Nations people and to Inuit communities. We work with the provinces to ensure our health care system serves the needs of Canadians. Également disponible en français sous le titre : XXXXXXXXXXXXXXXXXXXXXXXX To obtain additional information, please contact: Health Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: Toll free: Fax: TTY: publications@hc-sc.gc.ca This publication can be made available in alternative formats upon request. Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2015 Publication date: Month 2015 This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. Cat.: XXXXXXX ISBN: XXXXXXX Pub.: XXXXXXX

3 Forward Guidance documents are meant to provide assistance on how to comply with governing statutes and regulations. Guidance documents also provide assistance to staff on how Health Canada mandates and objectives should be implemented in a manner that is fair, consistent and effective. Guidance documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches to the principles and practices described in this document may be acceptable provided they are supported by adequate justification. Alternate approaches should be discussed in advance with the relevant program area to avoid the possible finding that applicable statutory or regulatory requirements have not been met. As a corollary to the above, it is equally important to note that Health Canada reserves the right to request information or material, or define conditions not specifically described in this document, in order to allow the Department to adequately assess the safety, efficacy or quality of a therapeutic product. Health Canada is committed to ensuring that such requests are justifiable and that decisions are clearly documented. This document should be read in conjunction with relevant sections of other applicable guidance documents. Preparation and Submission of Summary Reports for Marketed Health Products i

4

5 Table of Contents 1 Introduction Objectives Scope and Application Guiding Principles Background Annual Summary Reports Preparing and Maintaining Annual Summary Reports Acceptable Annual Summary Report Format Periodic Benefit-Risk Evaluation Report (PBRER) Periodic Safety Update Report (PSUR) Annual Summary Report Alternative Format Canadian-Specific Sections Notifying Health Canada of a Change in the Risks and Benefits of a Health Product Use of Foreign Reviews Issue-Related Summary Reports Acceptable Issue-Related Summary Report Format Submission Procedures for Annual Summary Reports and Issue-Related Summary Reports General Considerations When to Submit an Annual Summary Report or Issue-Related Summary Report to Health Canada Instructions for Submitting Annual Summary Reports and Issue-Related Summary Reports for Drugs ectd Format Requirements Non-eCTD Format Requirements Cover Letter Health Canada s Review of Annual Summary Report and Issue-Related Summary Report Submissions Status Requests Appendix 1: Requirements for Lower Risk Health Products (e.g., certain over-the-counter (OTC) drugs and natural health products) Appendix 2: Regulations Pertaining to Annual Summary Reports and Issue-Related Summary Reports Appendix 3: Glossary Appendix 4: Contact Information Appendix 5: List of Relevant Guidance Documents Preparation and Submission of Summary Reports for Marketed Health Products iii

6

7 Introduction 1.1 Objectives This guidance document is intended to: define Health Canada s expectations for post-approval regulatory requirements for health products, and; provide an overview of the procedures for submitting annual summary reports and issue-related summary reports to Health Canada. An annual summary report is a comprehensive assessment of all known safety information for a marketed health product. It is prepared by the market authorization holder (MAH) to provide an update on the worldwide safety profile of a health product at defined intervals post-authorization, and submitted to Health Canada upon request. An issue-related summary report is a concise, critical analysis of a specific safety or effectiveness issue that may be related to a health product. It is prepared by the MAH at the request of Health Canada. 1.2 Scope and Application This guidance document provides MAHs with information on how to comply with the Food and Drugs Act, the Food and Drug Regulations, and the Natural Health Products Regulations with respect to the preparation and submission of annual summary reports and issue-related summary reports for marketed health products. The principles and practices outlined in this document apply to the following health products for human use: pharmaceutical drugs (prescription and non-prescription drugs, including generics); biologics; biotechnology products; radiopharmaceuticals; preventative vaccines; therapeutic vaccines; natural health products; and, medical devices (when part of a combination product submission). This guidance document does not apply to annual summary reports provided to pre-market Directorates as part of a submission. While these principles can be applied across all product lines, please see Appendix 1 for certain products that are within the scope of lower risk health products (e.g., certain over-the-counter (OTC) drugs and natural health products). 1.3 Guiding Principles Health Canada uses a lifecycle approach to continually promote high standards of health product vigilance, to protect the health and safety of Canadians, and to facilitate access to health products which are important to health and well-being. Preparation and Submission of Summary Reports for Marketed Health Products 1

8 In addition to Canadian legislative and regulatory requirements, Health Canada aligns health product vigilance with international best practices wherever possible. Health Canada, as an official member to the International Conference on Harmonisation (ICH) is committed to the adoption and implementation of ICH guidances. 1.4 Background According to the World Health Organization (WHO), pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. As the scope of health products regulated in Canada is broader than drugs, Health Canada uses the term health product vigilance in relation to the WHO definition. Health Canada encourages and monitors good vigilance practices (GVPs) by industry, reflecting the fact that industry is responsible for the safety and efficacy of their health products. MAHs have primary responsibility for the safety of any health products they sell, manufacture, import or distribute to the Canadian public, and must comply with all Canadian legislative and regulatory requirements. Health Canada has a shared responsibility to enforce Canadian legislative and regulatory requirements and monitor risks associated with marketed health products. In 1996, ICH endorsed the ICH E2C guidance on Clinical Safety Data Management: Periodic Safety Update Reports (PSURs) for Marketed Drugs, which provided guidance on the format and content of safety updates. The ICH E2C(R1) harmonized periodic safety reporting requirements for MAHs and provided a common international format. On April 1, 2010, Health Canada adopted ICH E2C(R1) and implemented a two year risk-prioritized PSUR Regulatory Review Pilot. Since that time, the science of pharmacovigilance has evolved globally, prompting reassessment of the role of the PSUR in the spectrum of safety documents submitted to regulatory authorities. In December 2012, ICH finalized the ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER) guidance. On March 1, 2013, Health Canada announced to stakeholders that it has adopted the ICH E2C(R2). This guidance is intended to ensure that worldwide safety experience is provided to authorities at defined times after marketing, with maximum efficiency and avoiding duplication of effort. The PBRER format will allow MAHs to prepare a comprehensive, concise, and critical analysis of new or emerging information on the risks and benefits of their health products and to enable an evaluation of the product s overall benefit-risk profile. 2 Preparation and Submission of Summary Reports for Marketed Health Products

9 Annual Summary Reports In accordance with the Food and Drug Regulations 1, the MAH must, on an annual basis and whenever requested by the Minister of Health, conduct a concise, critical analysis of the adverse reactions and serious adverse reactions for a health product and prepare a summary report with respect to the reports received during the previous twelve months. When preparing the report, the MAH must determine whether or not there has been a significant change in the benefit-risk profile of the health product. The current interpretation of benefit-risk profile for a health product is a reflection of the overall balance of the product's potential benefits with its identified risks as revealed through safety and efficacy evidence, and through consideration of how that evidence contextualizes with normal conditions of use on the market. 2 If the MAH concludes that there has been a significant change in the benefit-risk profile, they must notify the Minister immediately. If Health Canada determines that an examination of the safety and/or effectiveness of a health product are warranted, a request may be made to the MAH to submit an annual summary report, and/or the case reports of all adverse reactions that are known to the MAH. In accordance with the Natural Health Products Regulations 3, the MAH must, on an annual basis, prepare and maintain a summary report that contains a concise and critical analysis of all domestic adverse reactions to a natural health product, and all foreign serious unexpected adverse reactions to a natural health product taken at the recommended dose, reported during the previous twelve months. If the Minister has reasonable grounds to believe that the natural health product may no longer be safe when used under the recommended conditions of use, the Minister may request any summary reports, interim summary reports and all adverse reactions for which a case report is required, to be submitted to Health Canada within 30 days after the day on which the request is received by the MAH. 2.1 Preparing and Maintaining Annual Summary Reports The MAH must ensure that all regulatory requirements of the Food and Drug Regulations, and the Natural Health Products Regulations are met and any relevant Health Canada guidance documents are applied. There may be instances when the MAH choses to engage in a contractual agreement with another party whereby they carry out certain regulatory responsibilities on behalf of the MAH (e.g., maintaining records related to adverse reaction (AR) data and preparing annual summary reports). In these cases, it remains the responsibility of the MAH to ensure that any documents requested by Health Canada are sent accordingly. For further guidance on GVPs with respect to drug post-approval reporting requirement responsibilities of the MAH and the importer, refer to Health Canada s Good Pharmacovigilance Practices (GVP) Guidelines (GUI-0102). The MAH is required to prepare and maintain annual summary reports for all of their licensed health products. The requirement to prepare annual summary reports begins on the date that the MAH receives Canadian market authorization for the health product. These reports need to be submitted to Health Canada only in certain circumstances (see Section 4.2). However, all annual summary reports must be maintained by the MAH on site or be easily accessible and, when requested, be submitted to Health Canada within 30 calendar days unless otherwise specified. The selected 12-month period for the annual summary report is specified by the MAH. It is the preference of Health Canada that annual summary reports be prepared with harmonized Data Lock Points (DLPs) based on the Preparation and Submission of Summary Reports for Marketed Health Products 3

10 International Birth Date 4 (IBD) of the active substance. If the MAH is unable to identify the IBD, they should refer to the EU reference dates (EURD) list 5. For natural health products, the date of first licensing in Canada should be used. 2.2 Acceptable Annual Summary Report Format MAHs may prepare summary reports in the Periodic Benefit-Risk Evaluation Report (PBRER) format in accordance with the standards defined in the ICH E2C(R2) 6 guidance, or the Periodic Safety Update Report (PSUR) format in accordance with the standards defined in the ICH E2C(R1) 7 guidance. Health Canada has been accepting annual summary reports in either PSUR or PBRER format since the ICH E2C(R2) guidance was adopted. The vast majority of MAHs have made the transition to PBRER reporting, and as of January 2015 Health Canada s preference is that MAHs prepare annual summary reports in PBRER format Periodic Benefit-Risk Evaluation Report (PBRER) PBRERs should be prepared annually using the time interval for submission outlined in the ICH E2C(R2) guidance. For further guidance on the format and content of a PBRER please refer to the ICH E2C(R2) guidance document 8. Line listings are not required if MAHs prepare annual summary reports in the PBRER format Periodic Safety Update Report (PSUR) The PSUR format is also acceptable to Health Canada. Unless otherwise specified by Health Canada, PSURs should be prepared annually using the time interval for submission outlined in the ICH E2C(R1) guidance, which is available upon request to Health Canada Annual Summary Report Alternative Format An annual summary report needs to take into account not only adverse reaction reports but also consumer complaints and other publicly available information that might be necessary for the analysis. MAHs should supplement their collection and analysis of AR and complaint reports a relating to patient symptoms, with external information searches regarding emergent safety issues (e.g. Canada Vigilance, foreign regulatory websites, scientific literature, etc.). The appropriate timing, frequency and nature of environmental scanning depend on such factors as the risk profile of the product, any specific emergent issues, the scheduling of the summary report, etc. The preparation of annual summary reports should result in increasing cumulative knowledge of real-world use that can be compared against referenced safety information (e.g. product monographs, core company data sheets, core company safety information, etc.) If an MAH is not able to prepare an annual summary report in either PBRER or PSUR format or if these formats are not optimal or appropriate, a simpler or alternate format may be used. Health Canada expects that such a report would contain the following sections b : Introduction a It is desirable tor records of symptomatic product complaints to include the four basic vigilance elements: product name, unique patient identifier (e.g. initials, age), the nature of the reaction/symptoms, and reporter contact information. b See Appendix 1 for a format for certain consumer health products. 4 Preparation and Submission of Summary Reports for Marketed Health Products

11 Summary of changes (if any) to what is known about the product s safety, based on information collected during the reporting period Significant domestic or foreign regulatory actions (if any) bearing on safety during the reporting period Patient exposure (e.g. estimated from sales figures) A critical analysis to determine if there has been, since the last reporting period: Any significant change in the characteristics of expected adverse reactions and/or the overall safety profile of the health product (e.g., severity, outcome, target population, changes in effectiveness, use patterns) Serious unexpected reactions, placing into perspective the cumulative reports since marketing Non-serious unexpected reactions in vulnerable sub-populations An increased reporting frequency of expected reactions, including comments on whether it is believed the data reflect a meaningful change in AR occurrence Significant changes in reporting rates, including consideration of patient exposure Any new safety issues identified for the following: o drug interactions o experience with overdose, deliberate or accidental, and its treatment o drug abuse, misuse, or off-label use o positive or negative experiences during pregnancy or lactation o experience in special patient groups (e.g., children, elderly, organ impaired) o effects of long-term exposure Other information needed for the analysis Conclusion as to whether there has been a significant change in what is known about the risks and benefits of the health product during the period covered by the report Adverse reactions line listing(s) and summary tabulations The information included in the annual summary report will vary depending on the adverse reaction cases reported to the MAH. A lack of significant new information should be mentioned for each section. 2.3 Canadian-Specific Sections Although standardized periodic summary reports (i.e. PBRERs and PSURs) are used globally, regional differences may exist and should be accounted for. Below are examples of special considerations related to medical practice or populations in Canada that should be considered when preparing an annual summary report: Include information such as the epidemiology of the medical condition(s) or risk factors that reflect the authorized indication(s) in Canada in cases where it varies from the authorized indication(s) in other jurisdictions; Reference the latest available version of the Terms of Market Authorization [e.g., Canadian Product Monograph (PM)]; Include information related to Canadian patient exposure (when relevant); Provide post-marketing experience in the Canadian context; Discuss pharmacovigilance activities within the Canadian context; this could involve monitoring of domestic adverse events known to the MAH, and reconciliation of such reaction(s) with Health Canada s Canada Vigilance Database; and Preparation and Submission of Summary Reports for Marketed Health Products 5

12 Include information that is applicable to the Canadian context, in relation to risk minimization strategies and evaluation of effectiveness of risk minimization activities. Canadian-specific section(s) can be provided in the form of a Canadian-specific summary report or as an appendix or annex to an already prepared summary report. 2.4 Notifying Health Canada of a Change in the Risks and Benefits of a Health Product In accordance with the Food and Drug Regulations 1, in preparing the annual summary report, the MAH must determine whether there has been a significant change in what is known about the risks and benefits of the drug. If the MAH concludes from the annual summary report that there has been a significant change, they must inform Health Canada immediately in a letter sent to the Office of Submissions and Intellectual Property (OSIP). The notification should include the most recent completed annual summary report, and a cover letter indicating that the information is being sent pursuant to the reporting requirements detailed in C (4) of the Food and Drug Regulations. The Marketed Health Products Directorate (MHPD) may request additional information as a follow-up to such a notification. For natural health products, in addition to complying with regulatory requirements to report safety and efficacy information, Health Canada expects that MAHs will inform MHPD if the MAH concludes from the annual summary report that there is a significant change in what is known about the risks and benefits of a natural health product. Examples of a significant change in what is known about the risks and benefits of a health product include a significant change in the frequency or severity of a known risk (e.g., a sudden increase in reporting of QT prolongation and torsades de pointes), or the identification of a previously unknown serious risk (e.g., a new risk of liver failure). 2.5 Use of Foreign Reviews Reviews completed by regulatory authorities in the United States (US Food and Drug Administration) and the European Union s centralized procedure (European Medicines Agency) should be provided if available. The use of reviews from other foreign regulatory authorities may also be considered (e.g., Switzerland s Swissmedic; Australia s Therapeutic Goods Administration; and Singapore s Health Sciences Authority). 6 Preparation and Submission of Summary Reports for Marketed Health Products

13 Issue-Related Summary Reports Health Canada may request at any time that the MAH perform a further analysis of a specific safety issue by requesting that an issue-related summary report be submitted for the specific safety issue. For example, an issuerelated summary report may be requested as a follow-up to a PSUR or PBRER review. Pursuant to section C of the Food and Drug Regulations, Health Canada may, for the purposes of assessing the safety and effectiveness of a drug, request in writing that the MAH submit an issue-related summary report which contains a concise, critical analysis of the adverse drug reactions and serious adverse drug reactions to a drug. Typically, a 30 day period is requested for the submission of the report; however, the period may be shorter than 30 days if the information is required on an expedited basis in order to determine whether the drug poses a serious and imminent risk to human health. There are no provisions in the Natural Health Products Regulations for issue-related summary reports. However, for the purposes of assessing the safety and effectiveness of natural health products, Health Canada may on occasion request in writing that the MAH submit an issue-related summary report which contains a concise, critical analysis of the adverse reactions and serious adverse reactions to a natural health product. 3.1 Acceptable Issue-Related Summary Report Format The information requested in an issue-related summary report should contain, but is not limited to, the following: Definition used for the adverse event of interest; Description of the search strategy to retrieve the cases; Detailed summary analysis of the cases. Information should include, but not be limited to: tabulation of all events; MAH comments on the cases; summary analysis of the temporal relationship between health product administration and the occurrence of the event; and summary analysis of possible risk factors and confounding variables; Canadian and international patient exposure data using both patient-years and total number of patients exposed; A conclusion as to the safety and/or the effectiveness of the health product with regards to the occurrence of these events and if applicable, any planned risk mitigating actions or change to the Risk Management Plan, Product Monograph, or labelling; Copy of all the Council for International Organizations of Medical Sciences (CIOMS) reports for the adverse event of interest reported with the use of the product since its international birth date. Preparation and Submission of Summary Reports for Marketed Health Products 7

14

15 Submission Procedures for Annual Summary Reports and Issue-Related Summary Reports 4.1 General Considerations MAHs are strongly encouraged to consider the following when preparing annual summary reports and issue-related summary reports: Include the most recent data available unless otherwise indicated; Incorporate Canadian-specific data and information when possible (refer to section 2.3 for more detail); Provide a foreign review report (when available); The submission should be provided in either English or French. 4.2 When to Submit an Annual Summary Report or Issue-Related Summary Report to Health Canada Annual summary reports and issue-related summary reports should be submitted in, but are not limited to, the following circumstances: If a summary report is requested by Health Canada; To fulfill commitments for market authorization [e.g., Notice of Compliance with Conditions (NOC/c)]; or If the MAH concludes that there has been a significant change in what is known about the risks and benefits of the health product (e.g., a serious safety issue which may significantly affect the benefit-risk profile of the health product). In this case, Health Canada must be notified in writing immediately (see Health Canada contact information provided in Appendix 4). Annual summary reports and issue-related summary reports may be requested at any time by Health Canada as part of an ongoing safety review. Under the current regulatory framework, Health Canada may request additional information on a case-by-case basis or in follow-up to an annual summary report or issue-related summary report review. Annual summary reports and issue-related summary reports, when requested, are to be submitted to Health Canada within 30 calendar days or unless otherwise specified. 4.3 Instructions for Submitting Annual Summary Reports and Issue-Related Summary Reports for Drugs All annual summary reports and issue-related summary reports should be provided (when necessary) to Health Canada in electronic format. No paper copies should be provided, with the exception of the cover letter (refer to section 4.4 for more detail). Electronic documents should be submitted as Portable Document Format (PDF) files. PDF versions of documents should be generated from electronic source documents and not from scanned material, except where access to the source electronic file is unavailable or where a signature is required. Preparation and Submission of Summary Reports for Marketed Health Products 9

16 ectd Format Requirements Health Canada strongly recommends that electronic documents be provided in electronic common technical document (ectd) format. Annual summary reports and issue-related reports provided in ectd format should be prepared using applicable sections of the Guidance Document: Preparation of Drug Regulatory Activities in Electronic Common Technical Document (ectd) Format published on the Health Canada Website Non-eCTD Format Requirements Alternatively, Health Canada will also accept electronic documents in non-ectd electronic-only format. Annual summary reports and issue-related reports provided in non-ectd electronic-only format should be prepared using applicable sections of the document: Health Canada s requirements for filing regulatory activities in non-ectd electronic-only format published on the Health Canada Website. The annual summary report should be filed in the section "5.3.6 Reports of Postmarketing Experience" and the issue-related summary report should be filed in the section " Other Pharmacovigilance Information" using the structured template recommended in "Appendix D: Common Technical Document (CTD) Format" of the guidance document Preparation of Drug Regulatory Activities in the Common Technical Document (CTD) Format. 4.4 Cover Letter All submissions should be accompanied by both an electronic and a paper cover letter. MAHs should address the cover letter to OSIP. The cover letter should indicate the submission type as well as the reason for filing: To inform Health Canada of a significant change in what is known about the risks and benefits of the health product; REQUESTED PERIODIC PSUR/PBRER - requested by Health Canada (for example Risk Management Plan (RMP) follow-up or post-authorization commitment); REQUESTED AD HOC PSUR/PBRER - submitted as a one-time request made by either the premarket review directorate (reviewing the associated regulatory submission) or by MHPD (the requestor should be specified in the cover letter). ISSUE-RELATED SUMMARY REPORT- submitted as a one-time request made by MHPD (the requestor should be specified in the cover letter). 4.5 Health Canada s Review of Annual Summary Report and Issue-Related Summary Report Submissions Reviews of annual summary reports and issue-related summary reports are conducted by the MHPD. Reviews of annual summary reports related to a submission (e.g., PSUR-c / PBRER-c), are conducted by the respective premarket review Directorate (e.g., TPD, BGTD, NNHPD). Possible outcomes of Health Canada s reviews of annual summary reports and issue-related summary reports reviews may include, but are not limited to, the following: continuous surveillance / monitoring; additional assessments or safety reviews; 10 Preparation and Submission of Summary Reports for Marketed Health Products

17 a request that the MAH submit future annual summary report(s) or an issue-related summary report; or, a request that the MAH submit clarification on information provided in the submission. During the review of an annual summary report or an issue-related summary report, Health Canada may communicate in writing with the MAH to clarify information. If deficiencies have been identified, timelines for a response by the MAH will be included in a letter sent by Health Canada. The timelines may vary depending on the safety issue being managed and the type and amount of information being sought. The MAH is generally provided with a minimum of 30 days to respond. 4.6 Status Requests For drugs, MAHs are able to access information about their own submissions via the Drug Submission Tracking System - Industry Access (DSTS-IA). MAHs with questions about the status or progress of their submission may contact the relevant bureau (see Appendix 4 for contact information). Information will be provided to MAHs in keeping with the confidentiality of the process and without pre-empting the final decision of Health Canada on the disposition of the submission. Preparation and Submission of Summary Reports for Marketed Health Products 11

18

19 Appendix 1: Requirements for Lower Risk Health Products (e.g., certain over-thecounter (OTC) drugs and natural health products) Annual summary reports summarize and integrate new cumulative safety knowledge gained from experience during the reporting period. For products that have already been shown - with a high degree of certainty - to be inherently safe when used in the real world such reports will not likely yield significant new knowledge; as long as significant new knowledge is considered and (if necessary) reported, summary reporting requirements may be kept to a reasonable minimum. Hard-surface disinfectants and products at the cosmetic-drug interface (i.e. cosmetic-like drugs), for example, are likely to fall into this category. Health Canada expects that the annual summary report for these products should contain the following sections: Summary of changes, if any, to what is known about the product s safety, based on information collected during the reporting period Significant regulatory actions, if any, bearing on safety (domestic and foreign) during the reporting period A critical analysis to determine if there has been, since the last reporting period: o Any significant change in the overall safety profile of the product o Significant changes in reporting rates o Any new safety issues identified Other information needed for the analysis Conclusion, if any, as to whether there has been a significant change in what is known about the risks and benefits of the health product during the period covered by the report Adverse reactions line listing(s), if any, and summary tabulations Annual summary reports and issue-related summary reports should be submitted in, but are not limited to, the following circumstances: If a summary report is requested by Health Canada; If the MAH concludes that there has been a significant change in what is known about the risks and benefits of the health product (e.g., a serious safety issue which may significantly affect the benefit-risk profile of the health product). In this case, Health Canada must be notified in writing without delay (see Health Canada contact information provided in Appendix 4). Preparation and Submission of Summary Reports for Marketed Health Products 13

20

21 Appendix 2: Regulations Pertaining to Annual Summary Reports and Issue- Related Summary Reports The sections of the applicable regulations that set out the summary reporting requirements are listed below. Food and Drug Regulations Prohibition and Serious Adverse Drug Reaction Reporting (C , C ) Prohibition C No manufacturer shall sell a drug unless the manufacturer complies with the conditions set out in sections C to C Serious Adverse Drug Reaction Reporting C The manufacturer shall submit to the Minister a report of all information relating to the following serious adverse drug reactions within 15 days after receiving or becoming aware of the information, whichever occurs first: (a) any serious adverse drug reaction that has occurred in Canada with respect to the drug; and (b) any serious unexpected adverse drug reaction that has occurred outside Canada with respect to the drug. Annual Summary Report and Case Reports (C ) C (1) The manufacturer shall prepare an annual summary report of all information relating to adverse drug reactions and serious adverse drug reactions to the drug that it received or became aware of during the previous 12 months. (2) The annual summary report shall contain a concise, critical analysis of the adverse drug reactions and serious adverse drug reactions to the drug. (3) In preparing the annual summary report, the manufacturer shall determine, on the basis of the analysis referred to in subsection (2), whether there has been a significant change in what is known about the risks and benefits of the drug during the period covered by the report and shall include its conclusions in this regard in the summary report. (4) If, in preparing the annual summary report, the manufacturer concludes that there has been a significant change, it shall notify the Minister without delay, in writing, unless this has already been done. (5) The Minister may, for the purposes of assessing the safety and effectiveness of the drug, request in writing that the manufacturer submit to the Minister one or both of the following: (a) the annual summary reports; Preparation and Submission of Summary Reports for Marketed Health Products 15

22 (b) the case reports relating to the adverse drug reactions and serious adverse drug reactions to the drug that are known to the manufacturer. (6) The Minister shall, after giving the manufacturer an opportunity to be heard, specify a period for the submission of the annual summary reports or case reports, or both, that is reasonable in the circumstances, and the manufacturer shall submit the reports within that period. Issue-related Summary Reports (C ) C (1) The Minister may, for the purposes of assessing the safety and effectiveness of the drug, request in writing that the manufacturer submit to the Minister an issue-related summary report. (2) The report shall contain a concise, critical analysis of the adverse drug reactions and serious adverse drug reactions to the drug, as well as case reports of all or specified adverse drug reactions and serious adverse drug reactions to the drug that are known to the manufacturer in respect of the issue that the Minister directs the manufacturer to analyze in the report. (3) The Minister shall, after giving the manufacturer an opportunity to be heard, specify a period for the submission of the report that is reasonable in the circumstances. The Minister may specify a period that is shorter than 30 days if the Minister needs the information in the report to determine whether the drug poses a serious and imminent risk to human health. (4) The manufacturer shall submit the report within the specified period. Maintenance of Records (C ) C (1) The manufacturer shall maintain records of the reports and case reports referred to in sections C to C (2) The manufacturer shall retain the records for 25 years after the day on which they were created. New Drugs (C , C ) C (1) Where a manufacturer has received a notice of compliance issued in respect of a new drug submission, an extraordinary use new drug submission, an abbreviated new drug submission, an abbreviated extraordinary use new drug submission or a supplement to any of those submissions, the manufacturer shall establish and maintain records, in a manner that enables an audit to be made, respecting (g) any failure of one or more distributed lots of the new drug to meet the specifications established for that new drug in the submission or supplement; and (h) any unusual failure in efficacy of that new drug. 16 Preparation and Submission of Summary Reports for Marketed Health Products

23 C No manufacturer shall sell a new drug unless the manufacturer has, with respect to all the manufacturer's previous sales of that new drug, furnished to the Minister... (c) a summary of a record respecting any information referred to in paragraph C (g) or (h), within 15 days of the day on which the manufacturer established the record. Natural Health Products Regulations (Section 24) Section (1) A licensee shall provide the Minister with (a) a case report for each serious adverse reaction to the natural health product that occurs inside Canada, within 15 days after the day on which the licensee becomes aware of the reaction; and (b) a case report for each serious unexpected adverse reaction to the natural health product that occurs inside or outside Canada, within 15 days after the day on which the licensee becomes aware of the reaction. (2) A licensee who sells a natural health product shall annually prepare and maintain a summary report that contains a concise and critical analysis of (a) all adverse reactions to the natural health product that have occurred inside Canada; and (b) all reactions for which a case report is required to be provided under subsection (1), that have occurred (i) during the previous 12 months, and (ii) at a dose used or tested for the diagnosis, treatment or prevention of a disease or for modifying organic functions in humans. (3) If after reviewing a case report provided under subsection (1) or after reviewing any other safety data relating to the natural health product, the Minister has reasonable grounds to believe that the natural health product may no longer be safe when used under the recommended conditions of use, the Minister may request that, within 30 days after the day on which the request is received, the licensee (a) provide to the Minister a copy of any summary report prepared under subsection (2); or (b) prepare and provide to the Minister an interim summary report containing a concise and critical analysis of (i) all adverse reactions to the natural health product that have occurred inside Canada, and (ii) all reactions for which a case report is required to be provided under subsection (1), that have occurred Preparation and Submission of Summary Reports for Marketed Health Products 17

24 (A) since the date of the most recent summary report prepared under subsection (2), and (A) at a dose used or tested for the diagnosis, treatment or prevention of a disease or for modifying organic functions in humans. 18 Preparation and Submission of Summary Reports for Marketed Health Products

25 Appendix 3: Glossary Adverse reaction (AR) For the purpose of this guidance document, adverse reaction means a noxious and unintended response to a marketed health product covered by this document, and includes "adverse drug reaction" as defined in the Food and Drug Regulations 1 and "adverse reaction" as defined in the Natural Health Products Regulations 9. Drug According to the Food and Drugs Act 1, a drug includes any substance or mixture of substances manufactured, sold or represented for use in: a. the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms, in human beings or animals, b. restoring, correcting or modifying organic functions in human beings or animals, or c. disinfection in premises in which food is manufactured, prepared or kept. European Union Reference Date (EURD) The European Union reference date corresponds to the date of the first marketing authorisation of a medicine containing that active substance or that combination of active substances in the EU, or alternatively the earliest of the known dates of the marketing authorisations for a medicine containing that active substance or that combination of active substances. Foreign reviews (also referred to as foreign review reports) Scientific safety, efficacy, and quality reports prepared by foreign regulatory authorities, upon which foreign regulatory decisions on health products are based. Includes initial scientific assessments, regulatory correspondence with the sponsor/applicant, follow-up assessments, and the final decision (e.g., positive, negative, conditional). Includes, where applicable, risk management plans and on-site evaluation reports (or equivalent). Does not include the data package filed with the foreign regulatory authority. Health product For the purpose of this guidance document includes products regulated under the Food and Drug Regulations ("drugs") and the Natural Health Products Regulations ("natural health products"). Drugs include both prescription and non-prescription pharmaceuticals; biotechnology products and biologically-derived products such as vaccines, serums, and blood -derived products; disinfectants; and radiopharmaceuticals. Note however, as set out in Section 1.2, that only some of these health products fall within the scope of this guidance document. International Birth Date (IBD) The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world. International Conference on Harmonisation (ICH) The International Conference on Harmonisation is a joint regulatory-industry initiative pertaining to the international harmonisation of regulatory requirements for drug products. This is carried out via the development and implementation of harmonised technical guidelines and standards for the development, registration and surveillance of pharmaceutical products. Health Canada is committed to the adoption and implementation of ICH guidances. Preparation and Submission of Summary Reports for Marketed Health Products 19

26 Market authorization holder (MAH) For the purpose of this guidance document, market authorization holder (MAH) means the entity that holds the Notice of Compliance, the Drug Identification Number (DIN), the Natural Product Number (NPN), the Homeopathic Medicine Number (DIN-HM), or the product licence. Natural health product (NHP) A substance set out in Schedule 1 of the Natural Health Products Regulations 9 or a combination of substances in which all the medicinal ingredients are substances set out in Schedule 1 of the Natural Health Products Regulations, a homeopathic medicine or a traditional medicine that is manufactured, sold or represented for use in a. the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state or its symptoms in humans; b. restoring or correcting organic functions in humans; or c. modifying organic functions in humans, such as modifying those functions in a manner that maintains or promotes health. However, a natural health product does not include a substance set out in Schedule 2 of the Natural Health Products Regulations, any combination of substances that includes a substance set out in Schedule 2 of the Natural Health Products Regulations or a homeopathic medicine or a traditional medicine that is or includes a substance set out in Schedule 2 of the Natural Health Products Regulations. Periodic Benefit Risk Evaluation Report (PBRER) The PBRER is a pharmacovigilance document intended to provide a comprehensive, concise, and critical analysis of new or emerging information on the risks of the health product, and on its benefit in approved indications, to enable an appraisal of the product s overall benefit-risk profile. The updated ICH E2C(R2) guidance ensures that annual summary reports for marketed health products have the role of being periodic benefit-risk evaluation reports by covering: Safety evaluation, evaluation of all relevant available information accessible to MAHs and benefit-risk evaluation. Pharmacovigilance Defined by the World Health Organization (WHO) as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. Periodic Safety Update Report (PSUR) The PSUR is a practical and achievable mechanism for summarizing interval safety data, and for conducting an overall safety evaluation. It is a tool for MAHs to conduct systematic analyses of safety data on a regular basis. In addition to covering ongoing safety issues, the PSUR should also include updates on emerging and/or urgent safety issues, and major signal detection and evaluation that are addressed in other documents. Serious adverse reaction For the purpose of this guidance document, serious adverse reaction means a noxious and unintended response to a marketed health product covered by this document that occurs at any dose and that requires in-patient hospitalization or prolongation of existing hospitalization, that causes congenital malformation, results in persistent or significant disability or incapacity, is a medically important event or reaction, is life-threatening or results in death and includes "serious adverse drug reaction" as defined in the Food and Drug Regulations 1 and "serious adverse reaction" as defined in the Natural Health Products Regulations Preparation and Submission of Summary Reports for Marketed Health Products

27 Terms of Market Authorization (TMA) The Terms of Market Authorization (TMA) are comprised of all labelling information (e.g., PM, prescribing information, inserts, etc.) that accompanies the Notice of Compliance (NOC) and/or in the document that assigns a DIN, and any related labelling material for health products. This information is derived from the review of information on the health product that is submitted for regulatory review and authorization, as required by the Food and Drug Act, and respective Regulations, (and as interpreted by guidance documents and policies). For natural health products, the TMA is all labelling information (e.g., risk information) that accompanies the product licence and/or document that assigns an NPN or DIN-HM, and any related material for labelling of the health product. Preparation and Submission of Summary Reports for Marketed Health Products 21

Health Products and Food Branch Inspectorate

Health Products and Food Branch Inspectorate Our Mandate: To manage and deliver a national compliance and enforcement program for blood and donor semen; cells, tissues and organs; drugs (human and veterinary); medical devices and natural health products,

More information

Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products*

Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products* Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products* (Effective Date: 2011-03-02) Canada Vigilance Adverse Reaction Monitoring Program and Database, a program of MedEffect

More information

Doc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021

Doc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021 National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034

More information

Public release of clinical information in drug submissions and medical device applications

Public release of clinical information in drug submissions and medical device applications Public release of clinical information in drug submissions and medical device applications Health Products and Food Branch March 10, 2017 Health Canada is the federal department responsible for helping

More information

NOTICE. Re: Guidance Document GD211: Guidance on the Content of Quality Management System audit reports

NOTICE. Re: Guidance Document GD211: Guidance on the Content of Quality Management System audit reports June 8, 2011 NOTICE Our file number: 11-110913-528 Re: Quality Management System audit reports is pleased to announce the release of the guidance document GD211: Guidance on the Content of. A draft version

More information

Health Canada s NHP Vigilance Activities

Health Canada s NHP Vigilance Activities Health Canada s NHP Vigilance Activities Canadian Health Food Association (CHFA) East October 3, 2013 Scott Sawler Director General Marketed Health Products Directorate Overview NHP Program & MHPD Activities

More information

Reporting Adverse Reactions to Marketed Health Products

Reporting Adverse Reactions to Marketed Health Products Reporting Adverse Reactions to Marketed Health Products Guidance Document for Industry Effective Date: May 23, 2018 Health Canada is responsible for helping Canadians maintain and improve their health.

More information

Auditor General of Canada to the House of Commons

Auditor General of Canada to the House of Commons 2011 Report of the Auditor General of Canada to the House of Commons FALL Chapter 4 Regulating Pharmaceutical Drugs Health Canada Office of the Auditor General of Canada The Fall 2011 Report of the Auditor

More information

July 11, Notice. Our file number:

July 11, Notice. Our file number: July 11, 2018 Notice Our file number: 18 107850 551 Release of the Therapeutic Products Directorate Statistical Report 2017/2018 for the Patented Medicines (Notice of Compliance) Regulations and Data Protection

More information

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility Recent developments in Pharmacovigilance from the Regulator s Perspective In strategy, competence, quality and flexibility Pharmacovigilance Regulatory Affairs Operations Medical Writing & toxicology Recent

More information

E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report Questions & Answers

E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report Questions & Answers E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report & Current version dated 31 March International Conference on Harmonisation of Technical Requirements

More information

GUIDANCE FOR CLINICAL TRIAL SPONSORS Clinical Trial Applications

GUIDANCE FOR CLINICAL TRIAL SPONSORS Clinical Trial Applications GUIDANCE FOR CLINICAL TRIAL SPONSORS Published by authority of the Minister of Health Date Adopted 2003/06/11 Effective Date 2003/06/25 Administrative Changes Date 2008/02/27 Health Products and Food Branch

More information

Explanatory Note to GVP Module VII

Explanatory Note to GVP Module VII 31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure

More information

Therapeutic Products Programme Holland Cross, Tower B 1600 Scott Street Address Locator # 3102D1 OTTAWA, Ontario K1A 1B6 March 24, 2000

Therapeutic Products Programme Holland Cross, Tower B 1600 Scott Street Address Locator # 3102D1 OTTAWA, Ontario K1A 1B6 March 24, 2000 Therapeutic Products Programme Holland Cross, Tower B 1600 Scott Street Address Locator # 3102D1 OTTAWA, Ontario K1A 1B6 March 24, 2000 00-003535 To: Main Trade Associations, Registrars of Medicine, Registrars

More information

Adjusting to Effectively Meet the New European Union Pharmacovigilance Requirements

Adjusting to Effectively Meet the New European Union Pharmacovigilance Requirements Adjusting to Effectively Meet the New European Union Pharmacovigilance Requirements Deirdre McCarthy Michelle Bulliard GRP Webinar 31 January 2013 Copyright 2013 Quintiles Your Presenters Deirdre McCarthy

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/816292/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report Draft finalised by the Agency in collaboration with Member

More information

ICH guideline E2C (R2) - questions and answers

ICH guideline E2C (R2) - questions and answers 25 August 2015 EMA/CHMP/ICH/271908/ Committee for Human Medicinal Products Step 5 Transmission to CHMP for adoption May Release for information May 30 Churchill Place Canary Wharf London E14 5EU United

More information

Guidance Document. Post Notice of Compliance (NOC) Changes: Safety and Efficacy Document

Guidance Document. Post Notice of Compliance (NOC) Changes: Safety and Efficacy Document Guidance Document Post Notice of Compliance (NOC) Changes: Safety and Efficacy Document Date Adopted: 2009/09/02 Revised Date: 2018/02/19 Effective Date: 2018/06/26 Health Canada is responsible for helping

More information

CANADA (HEALTH CANADA)

CANADA (HEALTH CANADA) 1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers

More information

CANADA (HEALTH CANADA)

CANADA (HEALTH CANADA) 1 GMP GAZETTE TM March 2015 HPFBI CANADA (HEALTH CANADA) Notice, Re: Regulatory Decision Summaries and Submissions Under Review Who s affected? Manufacturers of prescription drugs (pharmaceuticals and

More information

DRAFT GUIDANCE DOCUMENT Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs

DRAFT GUIDANCE DOCUMENT Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 DRAFT GUIDANCE DOCUMENT Applications Involving Human or Disinfectant Drugs This guidance document is being distributed for comment purposes only. 20 21 Published

More information

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Table of Contents Preamble... 3 Background... 3 What is a rare disease?... 3 What is an orphan drug?... 3 Unique Challenges

More information

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for

More information

VOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use

VOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use VOLUME 9 - PHARMACOVIGILANCE Medicinal Products for Human and Veterinary Use FOREWORD Directive 75/319/EEC as amended by Commission Directive 2000/38/EC of 5 th June 2000 and Directive 81/851/EEC as amended

More information

Pharmacovigilance System in Russia and the EAEU

Pharmacovigilance System in Russia and the EAEU Pharmacovigilance System in Russia and the EAEU Authors: Sergey Simeniv CEO X7 Research, CRO; Olga Latysheva Head of Pharmacovigilance Department X7 Research, CRO; Dmitry Kryuchkov Executive Director X7

More information

Notice. Guidance Document for Clinical Trial Sponsors: Clinical Trial Applications

Notice. Guidance Document for Clinical Trial Sponsors: Clinical Trial Applications May 29, 2013 Notice Our file number: 13-108409-403 for Clinical Trial Sponsors: Clinical Trial Applications Health Canada is pleased to announce the release of the finalized for Clinical Trial Sponsors:

More information

Regulatory Aspects of Pharmacovigilance

Regulatory Aspects of Pharmacovigilance Regulatory Aspects of Pharmacovigilance Deirdre Mc Carthy Pia Caduff-Janosa Training Course Uppsala 2012 Agenda Risk based approach to spontaneous reporting (incl clinical trials) -> Pia Caduff-Janosa

More information

Periodic Safety Update Reports. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017

Periodic Safety Update Reports. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 Periodic Safety Update Reports Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 Periodic Safety Update Reports - Evolution - Definition - Objective - Frequency and timing - EU vs USA and other non

More information

UK Standards for Pharmacovigilance Departments 2015

UK Standards for Pharmacovigilance Departments 2015 UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires

More information

FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS

FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013

More information

VM-ID: MU101_20_001e_WL - Wegleitung_HD - Hilfsdokument / V3.0 / dst / er / / 6

VM-ID: MU101_20_001e_WL - Wegleitung_HD - Hilfsdokument / V3.0 / dst / er / / 6 Contents 1 Abbreviations... 1 2 Requirements for signal reports... 2 3 Introduction... 2 4 Objective... 2 5 Scope... 2 6 Company signals (signals evaluated by the MAH)... 2 6.1 Signals involving a serious

More information

MASTER FILE PROCEDURES

MASTER FILE PROCEDURES MASTER FILE PROCEDURES Natural Health Products Directorate August 2006 Version 1.0 Our mission is to help the people of Canada maintain and improve their health, while respecting individual choices and

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE

More information

CANADA (HEALTH CANADA)

CANADA (HEALTH CANADA) 1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and

More information

GUIDELINES ON MEDICAL DEVICES

GUIDELINES ON MEDICAL DEVICES Ref. Ares(2016)1982736-26/04/2016 EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3

More information

CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS

CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS CMDh STANDARD OPERATING PROCEDURE ON THE PROCESSING OF PSUR SINGLE ASSESSMENT PROCEDURES FOR NATIONALLY AUTHORISED PRODUCTS 1. INTRODUCTION CMDh/322/2014/Rev.0 November 2014 This Standard Operating Procedure

More information

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies OFFICE FOR RESEACH PROCEDURE Sponsor Responsibilities in Investigator Initiated Studies 1. Purpose: To define Sponsor Responsibilities in the conduct of Investigator driven studies. 2. Scope: All phases

More information

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version No. : 02 Revision 1 :

More information

Drug Safety at Health Canada Presentation to CADTH

Drug Safety at Health Canada Presentation to CADTH Drug Safety at Health Canada Presentation to CADTH Kimby N. Barton Director, Bureau of Cardiology, Allergy and Neurological Sciences and Chair, Health Portfolio Risk Management Planning WG April 16, 2012

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE

More information

GUIDELINES ON MEDICAL DEVICES

GUIDELINES ON MEDICAL DEVICES EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON

More information

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports 24 October 2016 EMA/606369/2012 Rev.15 Procedure Management and Committees Support Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update

More information

Vaccine Prequalification Dossier

Vaccine Prequalification Dossier Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a

More information

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product Published by authority of the Minister of Health Date Adopted 2017/11/24 Effective Date 2017/11/24 Health Products

More information

Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)

Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) First Stakeholders Forum on the implementation of the new Pharmacovigilance legislation,

More information

PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use

PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides

More information

CADTH COMMON DRUG REVIEW. Procedure for the CADTH Common Drug Review

CADTH COMMON DRUG REVIEW. Procedure for the CADTH Common Drug Review CADTH COMMON DRUG REVIEW Procedure for the CADTH Common Drug Review AUGUST 2014 RECORD OF UPDATES TO THE PROCEDURE FOR THE CADTH COMMON DRUG REVIEW Update Original June 2003 1 January 2005 2 July 2005

More information

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS 1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS

More information

EphMRA Adverse Event Reporting Guidelines 2016

EphMRA Adverse Event Reporting Guidelines 2016 EphMRA Adverse Event Reporting Guidelines 2016 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European

More information

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised

More information

APPLICATION FOR INTERNATIONAL TRADE CERTIFICATE FOR NATURAL HEALTH PRODUCTS

APPLICATION FOR INTERNATIONAL TRADE CERTIFICATE FOR NATURAL HEALTH PRODUCTS APPLICATION FOR INTERNATIONAL TRADE CERTIFICATE FOR NATURAL HEALTH PRODUCTS NATURAL HEALTH PRODUCTS DIRECTORATE November 2007 Version 2.0 Our mission is to help the people of Canada maintain and improve

More information

Guidelines for Pharmacovigilance Inspections

Guidelines for Pharmacovigilance Inspections PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT

More information

Re: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance

Re: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance 07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing

More information

Pharmacovigilance System Master file

Pharmacovigilance System Master file IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file

More information

DRAFT GUIDANCE FOR INDUSTRY SUBMISSION AND INFORMATION REQUIREMENTS FOR EXTRAORDINARY USE NEW DRUGS (EUNDS)

DRAFT GUIDANCE FOR INDUSTRY SUBMISSION AND INFORMATION REQUIREMENTS FOR EXTRAORDINARY USE NEW DRUGS (EUNDS) DRAFT GUIDANCE FOR INDUSTRY SUBMISSION AND INFORMATION REQUIREMENTS FOR EXTRAORDINARY USE NEW DRUGS (EUNDS) This guidance document is being distributed for comment purposes only. Published by authority

More information

Technical Specifications for Testing Dried Marihuana for Medical Purposes. Published by authority of the Minister of Health

Technical Specifications for Testing Dried Marihuana for Medical Purposes. Published by authority of the Minister of Health Canada Gazette, Part II, publication of MMPR June 19, 2013 GUIDANCE DOCUMENT Technical Specifications for Testing Dried Marihuana for Medical Purposes Published by authority of the Minister of Health Controlled

More information

Regulatory Guidance How to Market a Biological (Schedule D) Drug

Regulatory Guidance How to Market a Biological (Schedule D) Drug Health Santé Canada Canada General Overview Regulatory Guidance How to Market a Biological (Schedule D) Drug This fact sheet provides general information about the approval and sale of Biological (Schedule

More information

Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs

Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs Joint Research Management Office (JRMO) Standard Operating Procedure (SOP) for: Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs SOP Number: 26a Version Number: 13.0 Effective Date: 31

More information

Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File

Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Turkish Medicines and Medical Devices Agency 16.02.2015 CHAPTER I... 2 1.1. Introduction... 2 CHAPTER II...

More information

CABINET DIRECTIVE ON STREAMLINING REGULATION

CABINET DIRECTIVE ON STREAMLINING REGULATION CABINET DIRECTIVE ON STREAMLINING REGULATION Her Majesty the Queen in Right of Canada, 2007 Catalogue No. BT22-110/2007 ISBN 978-0-662-49149-1 Table of Contents Our Commitment to Canadians... 1 1.0 Introduction...

More information

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01) 7 November 2011 EMA/863255/2011 EMA Comments on Implementing for Pharmacovigilance (PCIM/11/01) The Agency welcomes the public consultation on the Commission concept paper on the implementing measures

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/813938/2011 Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies Draft finalised by the Agency in collaboration with Member States and submitted

More information

Good Pharmacovigilance Practice Tunisian guidelines

Good Pharmacovigilance Practice Tunisian guidelines Good Pharmacovigilance Practice Tunisian guidelines Introduction Arab ministers of health came to a common decree (number 7) in their 37th regular meeting in March 2012. The Higher Technical Committee

More information

Good Vigilance Practice Module VI

Good Vigilance Practice Module VI Good Vigilance Practice Module VI Management and reporting of adverse reactions to medicinal products Stakeholders forum 27th February 2012 Gilles Touraille Signal Detection and Data Analysis Pharmacovigilance

More information

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012

More information

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach CADTH Symposium April 6, 2009 Maurica Maher, MD, MSc Associate Director Office of Legislative

More information

Development Safety Update Report Guidance

Development Safety Update Report Guidance Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational

More information

GUIDANCE DOCUMENT Master Files (MFs) - Procedures and Administrative Requirements

GUIDANCE DOCUMENT Master Files (MFs) - Procedures and Administrative Requirements GUIDANCE DOCUMENT Master Files (MFs) - Procedures and Administrative Requirements Published by authority of the Minister of Health Initial Draft Date 2008/08/05 Revision Date 2016/02/05 Effective Date

More information

Re: Docket No. FDA-2008-D-0386: International Conference on Harmonisation; Draft Guidance on E2F Development Safety Update Report; Availability.

Re: Docket No. FDA-2008-D-0386: International Conference on Harmonisation; Draft Guidance on E2F Development Safety Update Report; Availability. 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org November 03, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

DISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND

DISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND REASON FOR CHANGE: Wholesaler s licences are now issued by the Ministry of Health rather than Medsafe; clarify the approval process for the supply of products only to authorised facilities and healthcare

More information

Overview of global registration of vaccines

Overview of global registration of vaccines Overview of global registration of vaccines by Dr. Nora Dellepiane Workshop: Global Registration and Vaccine Shortage Taipei, Taiwan 6 to 10 March 2017 Outline of the presentation The objective of medicines

More information

Guideline on the Regulation of Therapeutic Products in New Zealand

Guideline on the Regulation of Therapeutic Products in New Zealand Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 March 2017 Section 1: Legislation Section summary This

More information

To: Associations, Pharmaceutical Sponsors, Clinical Research Investigators, Research Ethics Board and all other interested parties,

To: Associations, Pharmaceutical Sponsors, Clinical Research Investigators, Research Ethics Board and all other interested parties, Health Products and Food Branch Inspectorate Graham Spry Building, 3 rd Floor 250 Lanark Avenue Address Locator # 2003D Ottawa, Ontario K1A 0K9 August 29, 2008 08-120024-781 To: Associations, Pharmaceutical

More information

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile? Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies

More information

GUIDANCE FOR INDUSTRY Clinical Safety Data Management Definitions and Standards for Expedited Reporting ICH Topic E2A

GUIDANCE FOR INDUSTRY Clinical Safety Data Management Definitions and Standards for Expedited Reporting ICH Topic E2A GUIDANCE FOR INDUSTRY Clinical Safety Data Management Definitions and Published by authority of the Minister of Health 1995 Health Products and Food Branch Guidance Document Our mission is to help the

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 15 April 2014 EMA/876333/2011 Rev 3* (superseded version) Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 3) Date for coming into effect of first version 2 July 2012 Date

More information

Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington

Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational

More information

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8

More information

Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland

Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland AUT-G0095-1 15 AUGUST 2014 This guide does not purport to be an interpretation of law and/or regulations and is for

More information

Melbourne Health Guidelines Cover Sheet

Melbourne Health Guidelines Cover Sheet Melbourne Guidelines Cover Sheet NAME OF DEPARTMENT OFFICE FOR RESEARCH NAME OF DOCUMENT Clinical Trials Involving Therapeutic Products and Other Clinical Research NUMBER 18.8 ASSOCIATED MELBOURNE HEALTH

More information

NOTICE OF COMPLIANCE WITH CONDITIONS - QUALIFYING NOTICE

NOTICE OF COMPLIANCE WITH CONDITIONS - QUALIFYING NOTICE Therapeutic Products Directorate Holland Cross, Tower "B" 6th Floor, 1600 Scott Street Address Locator #3106B OTTAWA, Ontario K1A 0K9 January 10, 2014 Dossier Identifier: E141793 Control No.: 152211 [employee

More information

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012 New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,

More information

NIS Considerations - Bulgaria

NIS Considerations - Bulgaria NIS Considerations - Bulgaria An overview of the considerations when conducting Noninterventional Studies in Bulgaria Stuart McCully CHCUK Ltd NIS-C-BG-2014 1 Table of Contents Disclaimer 5 Copyright 5

More information

Risk Management Plan Guidance

Risk Management Plan Guidance 1 / 17 Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Office of Safety Ⅰ, Pharmaceuticals and Medical Devices Agency This English version is intended to be

More information

Re: Docket No. FDA-2012-D-0315: E2C(R2) Periodic Benefit-Risk Evaluation Report

Re: Docket No. FDA-2012-D-0315: E2C(R2) Periodic Benefit-Risk Evaluation Report 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org May 11, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville, MD

More information

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition The rules governing medicinal products in the European Union Volume 2B Notice to Applicants Medicinal products for human use Presentation and content of the dossier 1998 Edition EUROPEAN COMMISSION Directorate

More information

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines

More information

Q & A on PSUSA: Guidance document for assessors

Q & A on PSUSA: Guidance document for assessors 31 October 2017 EMA/518909/2016 Human Medicines Evaluation Division Q & A on PSUSA: Guidance document for assessors Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA),

More information

CTFG 10 September 2010

CTFG 10 September 2010 CTFG 10 September 2010 Clinical Trial Facilitation Group CTFG comments on the European Commission public consultation document CT3: draft detailed guidance on the collection, verification and presentation

More information

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation Safeguarding public health Third Stakeholders forum on the implementation of the new Pharmacovigilance Pharmacovigilance system master file an approach towards system simplification Joanna Harper Inspections,

More information

Species at Risk Act Policies and Guideline Series

Species at Risk Act Policies and Guideline Series Species at Risk Act Policies and Guideline Series Addressing Species at Risk Act Considerations Under the Canadian Environmental Assessment Act for Species Under the Responsibility of the Minister responsible

More information

PHARMACOVIGILANCE OF VETERINARY MEDICINAL PRODUCTS: MANAGEMENT OF ADVERSE EVENT REPORTS (AERS)

PHARMACOVIGILANCE OF VETERINARY MEDICINAL PRODUCTS: MANAGEMENT OF ADVERSE EVENT REPORTS (AERS) VICH GL24 (PHARMACOVIGILANCE: AERS) October 2007 For implementation at Step 7 PHARMACOVIGILANCE OF VETERINARY MEDICINAL PRODUCTS: MANAGEMENT OF ADVERSE EVENT REPORTS (AERS) Adopted at Step 6 of the VICH

More information

Fecal Microbiota Therapy Used in the Treatment of Clostridium difficile Infection Not Responsive to Conventional Therapies

Fecal Microbiota Therapy Used in the Treatment of Clostridium difficile Infection Not Responsive to Conventional Therapies Fecal Microbiota Therapy Used in the Treatment of Clostridium difficile Infection Not Responsive to Conventional Therapies Published by authority of the Minister of Health Date adopted 2015-03-27 Effective

More information

Health Products and Food Branch Inspectorate Graham Spry Building, 2 nd Floor 250 Lanark Avenue Address Locator # 2002B OTTAWA, Ontario K1A 0K9 December 1, 2007 07-117987-250 To: ALL INTERESTED PARTIES

More information